Bristol-Myers (BMY) discontinues late-stage colorectal cancer study
bristol myers squib BMY experienced a setback when it decided to cancel the late-stage trial RELATIVITY-123. In this Phase III, randomized, open-label, multicenter study, approximately 700 adult patients with stable microsatellites received a fixed-dose combination of Opdivo (nivolumab) and leratorimab, combined with Stivarga (regorafenib) or It was evaluated in comparison with trifluridine + tipiracil (TAS-102). […]
Bristol-Myers Squibb launches Kibosh into clinical trials for colorectal cancer candidate
Photo: Bristol-Myers Squibb Building in Munich / iStock Tati Campero Bristol-Myers Squibb is discontinuing a clinical trial studying a combination of Opdivo (nivolumab) and leratorimab, called Opdurag, in patients with stable microsatellite metastatic colorectal cancer. Data from a Phase III trial of the combination, known as Relativity-123, was reviewed by an independent data monitoring board […]